← All trials
NCT07227064
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 31, 2026
- First posted
- Nov 12, 2025
- Last posted
- Nov 13, 2025
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of South CarolinaLead sponsor
- Medical University of South CarolinaSponsor investigator
- Medical University of South CarolinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.